Le Lézard
Classified in: Health
Subjects: CCA, BFA, PET, FVT

Aratana Therapeutics to Report Third Quarter 2017 Financial Results



LEAWOOD, Kan., Oct. 5, 2017 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, will host a live conference call on Friday, November 3, 2017 at 8:30 a.m. ET to discuss financial results from the third quarter ended September 30, 2017.

Aratana Therapeutics logo

Interested participants and investors may access the audio webcast or use the conference call dial-in:

     1 (866) 364-3820 (U.S.) 
     1 (855) 669-9657 (Canada)
     1 (412) 902-4210 (International)

A replay of the third quarter results teleconference will be available the same day of the event by approximately 11 a.m. ET and an audio webcast will be accessible for 90 days in the Aratana Investor Room. For a replay of the call, use the below dial-in and conference ID 10112622:

     1 (877) 344-7529 (U.S.) 
     1 (855) 669-9658 (Canada
     1 (412) 317-0088 (International)

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative therapeutics for dogs and cats. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to dogs and cats in a capital and time efficient manner. The company's pipeline includes therapeutic candidates for the potential treatment of pain, inappetence, viral diseases, allergy, cancer and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.

Contacts
For investor inquires:
Craig Tooman
ctooman@aratana.com 
(913) 353-1026

For media inquiries:
Rachel Reiff
rreiff@aratana.com 
(913) 353-1050

SOURCE Aratana Therapeutics, Inc.


These press releases may also interest you

at 09:02
Second Genome, Inc., a leader in the development of novel therapeutics derived from the human microbiome, today announced the appointment of Anupama S. Hoey as chief business officer. In her role, Ms. Hoey will be leading all corporate development...

at 09:01
Research reported at the Alzheimer's Association International Conference (AAIC) 2018 in Chicago highlighted sex differences associated with dementia and Alzheimer's disease across the life course, including the first ever large-scale study of...

at 09:00
The "Microscopes - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East & Africa, and Latin...

at 09:00
MIAMI, July 23, 2018 /PRNewswire-PRWeb/ -- LegacyFit® heats up with a new opening in Doral, Fla. and two new locations to open in Orlando, Fla. later this year. Pro athletes hail LegacyFit® as a leading Bootcamp gym, and the fast-growing fitness...

at 09:00
According to Forbes, citing Brightfield Group, the global legal cannabis market is expected to reach USD 31.4 Billion by 2021. Currently, the global market is valued at about USD 7.7 Billion and is projected to grow at a CAGR of 60%, as other...

at 09:00
DURHAM, N.C., July 23, 2018 /PRNewswire-PRWeb/ -- Researchers have developed what appears to be a simple, minimally invasive, effective way to treat osteoarthritis (OA) in dogs that may prove to be of considerable importance in treating humans, too....




News published on 5 october 2017 at 16:30 and distributed by: